Zilucoplan (Zilbrysq) for generalized myasthenia gravis
Customize your policy alerts
Sign up for Ambetter Georgia Policy CP.PHAR.616 alerts
Get alerted when Policy CP.PHAR.616 changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing prior authorization and coverage criteria for Zilbrysq (zilucoplan) for treatment of generalized myasthenia gravis in adults under Ambetter Georgia lines of business.
Clarified that the required immunosuppressive therapy should be non-steroidal.
Added Imaavy and Vyvgart Hytrulo to the list of therapies that Zilbrysq should not be prescribed concurrently with.
For Medicaid and HIM, extended approval durations from 6 to 12 months and for Commercial, revised approval durations to include 'or to the member's renewal date, whichever is longer' as gMG is a chronic condition.
Added step therapy bypass for IL HIM per IL HB 5395.
Coverage Criteria for Zilbrysq (zilucoplan)
inv-01: Initial Approval — Generalized Myasthenia Gravis
Covered when ALL of the following are met:
inv-02: Continued Therapy — Generalized Myasthenia Gravis
Covered when ALL of the following are met:
Non–FDA approved indications that are not specifically addressed by this policy are not authorized unless the request includes sufficient documentation of efficacy and safety consistent with the applicable off‑label use policies. See commercial off‑label policy CP.CPA.09, health insurance marketplace off‑label policy HIM.PA.154, and Medicaid off‑label policy CP.PMN.53 for required evidence and documentation standards.
Zilbrysq must not be prescribed concurrently with the following products: Imaavy™, Soliris®/Bkemv™, Epysqli®, Ultomiris®, Rystiggo®, Vyvgart®, or Vyvgart® Hytrulo. The policy’s concurrent therapy exclusions were expanded during recent reviews to include additional complement and Ig therapies; providers should confirm current concomitant medication lists when submitting authorization requests.
Operational note: document any current or planned concomitant immunomodulatory or complement/Ig therapies in the prior authorization submission. Requests that propose concurrent use with the listed products will not meet coverage criteria and may be denied.
Use of Zilbrysq for diagnoses or clinical indications that do not meet the specific criteria listed in this policy, or for which supporting clinical documentation is not provided, is not authorized and may be considered not medically necessary. For non‑covered or off‑label indications, follow the referenced off‑label/no‑coverage policies and include supporting evidence if requesting exception or review.
Dosing, Administration, and Codes
inv-03: Dosing/Administration — Dosing for generalized myasthenia gravis (gMG)
Dosing for generalized myasthenia gravis (gMG):
Weight tiers: <56 kg = 16.6 mg SC once daily; 56 kg to <77 kg = 23 mg SC once daily; ≥77 kg = 32.4 mg SC once daily
| NDC not listed | Single-dose prefilled syringes: 16.6 mg/0.416 mL, 23 mg/0.574 mL, 32.4 mg/0.81 mL |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required and approval duration
Prior authorization is required for Zilbrysq; approval durations vary by line of business — Medicaid and HIM authorizations are for 12 months, while Commercial authorizations are for 6 months or to the member’s renewal date, whichever is longer.
- Submit request for prior authorization before initiating therapy.
- Expect authorization duration to follow benefit type: Medicaid/HIM = 12 months; Commercial = 6 months or to renewal date.
Prior authorization request must include applicable HCPCS coding and clinical info
Request authorization using applicable unclassified drug HCPCS codes (e.g., C9399 or J3490) and include the clinical information required by the policy; coding references in the policy are informational and do not by themselves authorize coverage.
Step therapy — document failure of required prior therapies
Initial approval requires documented failure of a corticosteroid, a cholinesterase inhibitor, and at least one non‑steroidal immunosuppressive therapy unless contraindicated or adverse effects are experienced; Appendix B lists therapeutic alternatives.
- Document prior trials and reasons for discontinuation or intolerance for each required therapy.
- If therapies are contraindicated, document the contraindication in the chart notes.
State-specific step therapy bypass — Illinois HIM (IL HB 5395)
Per Illinois law (IL HB 5395), the step therapy requirement does not apply for Illinois HIM requests as of 1/1/2026; follow this state-specific bypass when applicable.
- For Illinois HIM members, do not apply the corticosteroid/cholinesterase inhibitor/non‑steroidal immunosuppressive step requirements for requests dated on/after 1/1/2026.
Required documentation to support PA request
Providers must submit office chart notes, laboratory results, and other clinical information that demonstrate the member meets all approval criteria (diagnosis, anti‑AChR serology, MG‑ADL and MGFA scores, prior therapy history, weight, prescriber specialty, and REMS/vaccination status).
- Include baseline MG‑ADL score (must be ≥ 6) and MGFA class (II–IV).
- Include documentation of positive anti‑AChR antibody testing and current weight in kg.
- Document prescriber specialty (neurologist or consultation) and REMS/meningococcal vaccination status.
Document concomitant therapies and approved duration
Policy revisions changed approval durations and expanded the list of therapies that must not be prescribed concurrently; explicitly document any concomitant immunosuppressive or complement/Ig therapies and note the authorized approval duration in the record.
- Confirm and document that Zilbrysq is not being prescribed concurrently with listed products (e.g., Imaavy, Soliris/Bkemv/Epijkstra/Ultomiris/Rystiggo/Vyvgart/Vyvgart Hytrulo).
- Record the approval duration granted (per benefit type) in the member chart.
Denial risk if documentation or indication is insufficient
Requests that lack the required clinical documentation demonstrating the member meets all listed approval criteria or that seek coverage for non‑FDA indications without off‑label justification may be denied.
- Absence of baseline MG‑ADL, MGFA class, anti‑AChR serology, prior therapy trial documentation, or weight may result in denial.
- Off‑label indications must meet off‑label policy requirements (see referenced off‑label policies) or will not be authorized.
Coding implications may affect reimbursement and claim adjudication
Inclusion or exclusion of codes in this policy is informational only and does not guarantee coverage; improper or inconsistent coding can lead to claim denial or reimbursement issues.
- Reference current professional coding guidance before claim submission.
- Correct selection of HCPCS codes and consistency between the PA and claim are necessary to avoid denial.
Definitions and Safety Requirements
Background
Zilbrysq (zilucoplan) is a complement inhibitor FDA‑approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti‑AChR antibody positive. The product is supplied as single‑dose prefilled syringes in weight‑tiered strengths and is administered subcutaneously once daily at a dose matched to the patient’s weight tier. Because of the risk of meningococcal infection, Zilbrysq is available through a REMS program and patients should be vaccinated against meningococcal disease per REMS guidance prior to initiation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.